ArticleMovement disorders clinical practice2025
Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion in Parkinson's Disease: Real-World Short-Term Data on Tolerability, Infusion Rate Adjustments and Concomitant Medication.
Article in Movement disorders clinical practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Characteristics and Hospitalization Details of Patients with Advanced Parkinson's Disease Receiving Continuous Subcutaneous Infusion of Foslevodopa/Foscarbidopa: Real-World First-Year Descriptive Study from Japan.Neurology and therapy · 2026Article
- Real-world neuropsychiatric safety profile of foslevodopa/foscarbidopa infusion in advanced Parkinson's disease.Journal of neurology · 2026Article
- Real-world experience with foslevodopa/foscarbidopa in Germany: therapeutic insights and lessons learned.Neurological research and practice · 2026Review
- Observational Retrospective Cohort of Patient Support Program Data on Practical Experiences of Treatment with Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease: The ORCHESTRA Study.Neurology and therapy · 2026Article
- Review
- Continuous Subcutaneous Versus Intestinal Levodopa Infusion for Parkinson's Disease: A Real-World, Monocentric, Observational Study and Critical Review.Movement disorders clinical practice · 2026Observational
- Neuropsychiatric Adverse Events Associated With Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion in Clinical Practice: A Multicenter Study.European journal of neurology · 2026Observational
- Real-world outcomes and early discontinuation of foslevodopa/foscarbidopa in Parkinson's disease.Journal of neurology · 2026Article
- Neuropsychiatric and Cognitive Safety of Subcutaneous Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease: Insights From a Real-World Cohort.Journal of movement disorders · 2026Article
- Safety of opicapone in the elderly and very elderly population: an analysis of reported events in a global safety database.Clinical parkinsonism & related disorders · 2026Article
- Real-world implementation of continuous subcutaneous foslevodopa/foscarbidopa in advanced Parkinson's disease: first clinical experience from the Middle East.Therapeutic advances in neurological disorders · 2026Article
- Reply: "Navigating the Neuropsychiatric Risks of Foslevodopa/Foscarbidopa in Patients with Parkinson's Disease".Movement disorders clinical practice · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFoslevodopa/foscarbidopa (LDp/CDp) significantly reduced motor fluctuations in people with Parkinson's disease (PwP) in clinical trials, but its real-world tolerability and optimal dosing remain unclear.
objectivesTo assess tolerability, dosing patterns, and modifications to concomitant medication with LDp/CDp in clinical practice.
methodsA single-center retrospective cross-sectional analysis.
resultsThe LDp/CDp was initiated in 53 PwP (41% women, mean age 66 ± 11.3 years, mean disease duration 14.1 ± 5.7 years, median H&Y 4 (3-5); history of cognitive impairment: 40%, history of psychosis: 62%, previous device aided therapies failure: 39%). After an optimization period (18.4 ± 6.8 days), the mean Base hourly infusion rate was significantly higher than recommended (0.39 ± 0.18 vs. 0.32 ± 0.13 ml/h, p < 0.001) and the LDp/CDp was co-administered with MAO-B-inhibitors (50%), COMT-inhibitors (44%), and dopamine agonists (12%). Adverse events occurred in 40%: skin reactions (31%), psychosis (8%), falls (2%), and nausea (2%). Thirteen patients discontinued therapy.
conclusionsLDp/CDp may be an effective and well-tolerated non-surgical option for managing motor fluctuations in PD, though higher dosing and combination therapy are often required.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.